Sana Biotechnology, Inc. (NASDAQ:SANA – Get Free Report ) shares rose 6.8% during trading on Friday. The company’s shares traded as high as $6.48 and closed at $6.46. 42,773 shares were traded during trading, down 98% from the session’s average trading volume of 2,539,821 shares. The stock had previously closed at $6.05.
Analysts Set New Price Targets
Several research firms have issued reports on SANA. HC Wainwright reaffirmed their “buy” rating and set a $12.00 price target on shares of Sana Biotechnology in a research report on Thursday, May 9th. Rodman & Renshaw initiated coverage on shares of Sana Biotechnology in a research report on Wednesday, June 26th. The firm issued a “buy” rating and a $16.00 price target on the company. One analyst has rated the stock with a hold rating, and four have issued a buy rating. Sana Biotechnology currently has a “moderate buy” consensus rating and an average price target of $12.75, according to data from MarketBeat.com.
View the latest stock analysis for SANA
Sana Biotechnology trading up 5.8%
The company’s 50-day moving average price is $6.44 and its 200-day moving average price is $7.58. The company’s stock has a market capitalization of $1.42 billion, a P/E ratio of -4.18 and a beta of 1.45.
Sana Biotechnology, Inc. (NASDAQ:SANA – Get free report ) released its quarterly earnings report on Wednesday, May 8th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.02). Analysts on average expectation are that Sana Biotechnology, Inc. will post -1.15 earnings per share for the year.
Institutional investor inflows and outflows
Several large investors recently modified their holdings in SANA. The Vanguard Group increased its holdings in Sana Biotechnology by 1.2% in the third quarter. Vanguard Group acquired an additional 107,167 shares in the last quarter and now owns 9,167,585 shares valued at $35,479,000. SG Americas Securities LLC acquired a new stake in Sana Biotechnology in the fourth quarter, valued at approximately $99,000. China Universal Asset Management increased its holdings in Sana Biotechnology by 351.8% in the fourth quarter. China Universal Asset Management now owns 22,800 shares valued at $93,000 after acquiring an additional 17,753 shares in the last quarter. Arizona State Retirement System increased its holdings in Sana Biotechnology by 12.2% in the fourth quarter. Arizona State Retirement System now holds 27,527 shares of the company’s stock, valued at $112,000, after acquiring an additional 2,991 shares in the last quarter. Finally, Mirae Asset Global Investments Co., Ltd. increased its holdings in Sana Biotechnology by 286.4% in the fourth quarter. Mirae Asset Global Investments Co., Ltd. now holds 197,386 shares of the company’s stock, valued at $805,000, after acquiring an additional 146,303 shares in the last quarter. Institutional investors hold 88.23% of the company’s stock.
Sana Biotechnology Company Profile
(Get your free report)
Sana Biotechnology, Inc. is a biotechnology company focused on the use of genetically engineered cells as medicines. The company is developing in vitro and in vivo cell engineering platforms for a variety of therapeutic areas of unmet therapeutic need, including oncology, diabetes, central nervous system disorders and B-cell mediated autoimmunity.
References
Get Sana Biotechnology News and Ratings Daily – Enter your email address below to receive a concise summary of the latest news and analyst ratings on Sana Biotechnology and related companies every day with MarketBeat.com’s free email newsletter.
